JCI
EGRX

Jet Capital Investors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jet Capital Investors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-134,876
Closed -$9.44M – 47
2016
Q3 		$9.44M Buy
+134,876
New +$7.47M 0.67% 27

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Jet Capital Investors's EGRX Position: Q4 2016 in Review

Jet Capital Investors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2016, closing a stake of 134,876 shares — an estimated $9.44M sold.

Jet Capital Investors first reported a position in EGRX in Q3 2016 and held it in 1 quarter. The position peaked at $9.44M in Q3 2016. 149 funds tracked by Wall St. Rank hold EGRX as of Q4 2016.

  • Jet Capital Investors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • Jet Capital Investors sold 134,876 Eagle Pharmaceuticals, Inc. shares in Q4 2016, an estimated $9.44M.
  • Jet Capital Investors first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 1 quarter.
  • Jet Capital Investors's Eagle Pharmaceuticals, Inc. position peaked at $9.44M in Q3 2016.
  • 149 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2016.

Based on Jet Capital Investors's 13F filing for Q4 2016, filed 14 Feb 2017.